# AG Combined With Immunotherapy and SBRT in Patients With Potentially Resectable Pancreatic Cancer

> **NCT06080854** · PHASE2 · NOT_YET_RECRUITING · sponsor: **The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School** · enrollment: 108 (estimated)

## Conditions studied

- Pancreatic Carcinoma

## Interventions

- **DRUG:** Toripalimab
- **DRUG:** Gemcitabine
- **DRUG:** Nab paclitaxel
- **OTHER:** SBRT

## Key facts

- **NCT ID:** NCT06080854
- **Lead sponsor:** The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-11-10
- **Primary completion:** 2025-06-06
- **Final completion:** 2026-06-06
- **Target enrollment:** 108 (ESTIMATED)
- **Last updated:** 2023-10-12

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06080854

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06080854, "AG Combined With Immunotherapy and SBRT in Patients With Potentially Resectable Pancreatic Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06080854. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*